About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Stem Cell Transplantation for Newly Diagnosed M/M
Stem Cell Transplantation for Newly Diagnosed M/M
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
The Role of Plerixafor for Stem Cell Mobilization in the Setting of Autologous Stem Cell Transplantation
By
Parameswaran Hari
6 Videos
336 views
September 24, 2021
0 Comments
Login to view comments.
Click here to Login
Stem Cell Transplantation for Newly Diagnosed M/M
18:35
Rush University Medical Center
Upfront Autologous Transplant in Multiple Myeloma
Feat.
C. Hofmeister
34:28
2022 Community Oncology Conference
Treatment Conundrums in Myeloma
Feat.
S. Giralt
04:46
ASCO 2022 Conference Coverage
ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From th…
Feat.
C. Rodriguez
05:24
Luciano Costa
Dara-KRd, Autologous Transplantation, and MRD Response-Adapted Conso…
07:36
ASCO 2022 Conference Coverage
ASCO 2022 on the Changing Landscape in Post-Transplant Treatment of …
Feat.
A. Jakubowiak
08:09
Krina Patel
What Constitutes a Patient That Is Newly Diagnosed With MM as Eligib…
08:41
Parameswaran Hari
The Role of Plerixafor for Stem Cell Mobilization in the Setting of …
05:09
ASCO 2022 Conference Coverage
ASCO 2022 on Myeloma Developing Regimens Using Genomics (MyDRUG) Tri…
Feat.
S. Kumar
09:32
Christian Chabannon
Stem Cell Mobilization in MM
24:19
Dana-Farber Cancer Institute
Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…
Feat.
P. Richardson
10:29
Mary Kwok
Moving to Quadruplets in NDMM
05:37
PrecisCa
Induction Therapy for Patients With High-Risk NDMM: When to Utilize …
Feat.
A. Nooka
09:01
Mattia D'Agostino
IMS 2022 on Predictors of Unsustained Negativity in MRD(-) Transplan…
13:17
Andrzej Jakubowiak
IMS 2022 ATLAS: A Phase 3 Randomized Trial of Carfilzomib, Lenalidom…
09:09
Douglas W. Sborov
IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalido…
15:46
SOHO 2022 Tenth Annual Meeting
SOHO 2022: MM Frontline Therapy for Transplant-Eligible/Ineligible P…
Feat.
P. Voorhees
07:11
SOHO 2022 Tenth Annual Meeting
SOHO 2022 MM DEBATE: Auto + Maintenance Should Remain SoC in MM
Feat.
A. Krishnan
